RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $9.56 Average Target Price from Brokerages

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) have received an average rating of "Hold" from the thirteen brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $9.56.

A number of research firms have commented on RAPT. Wells Fargo & Company dropped their price objective on shares of RAPT Therapeutics from $17.00 to $4.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 12th. Stifel Nicolaus reissued a "hold" rating and issued a $2.00 price target (down from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th. HC Wainwright upgraded shares of RAPT Therapeutics from a "neutral" rating to a "buy" rating and set a $10.00 target price on the stock in a report on Thursday, December 26th. JPMorgan Chase & Co. cut RAPT Therapeutics from a "neutral" rating to an "underweight" rating in a report on Monday, November 11th. Finally, Piper Sandler cut shares of RAPT Therapeutics from an "overweight" rating to a "neutral" rating and decreased their price target for the stock from $8.00 to $2.00 in a research report on Monday, November 11th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Point72 Asset Management L.P. grew its holdings in RAPT Therapeutics by 176,725.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company's stock worth $2,157,000 after buying an additional 706,900 shares in the last quarter. Federated Hermes Inc. lifted its holdings in RAPT Therapeutics by 188.7% in the 2nd quarter. Federated Hermes Inc. now owns 796,080 shares of the company's stock valued at $2,428,000 after acquiring an additional 520,368 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of RAPT Therapeutics by 4,183.3% during the 2nd quarter. Acadian Asset Management LLC now owns 467,182 shares of the company's stock valued at $1,424,000 after purchasing an additional 456,275 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in shares of RAPT Therapeutics by 826.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 295,241 shares of the company's stock worth $900,000 after purchasing an additional 263,372 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its holdings in RAPT Therapeutics by 138.1% during the third quarter. Los Angeles Capital Management LLC now owns 201,439 shares of the company's stock worth $405,000 after buying an additional 116,853 shares in the last quarter. 99.09% of the stock is currently owned by institutional investors.

RAPT Therapeutics Price Performance

Shares of RAPT Therapeutics stock traded up $0.04 during trading on Friday, hitting $1.67. 1,127,595 shares of the stock were exchanged, compared to its average volume of 1,549,897. The firm's 50-day moving average price is $1.49 and its 200 day moving average price is $2.11. The stock has a market cap of $58.38 million, a price-to-earnings ratio of -0.60 and a beta of 0.07. RAPT Therapeutics has a 12-month low of $0.79 and a 12-month high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.09. As a group, research analysts forecast that RAPT Therapeutics will post -2.86 earnings per share for the current year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.